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Abstract
Objectives
The aim of this study was to compare the health care costs for patients using additional
homeopathic treatment (homeopathy group) with the costs for those receiving usual care
(control group).
Methods
Cost data provided by a large German statutory health insurance company were retrospec-
tively analysed from the societal perspective (primary outcome) and from the statutory
health insurance perspective. Patients in both groups were matched using a propensity
score matching procedure based on socio-demographic variables as well as costs, number
of hospital stays and sick leave days in the previous 12 months. Total cumulative costs over
18 months were compared between the groups with an analysis of covariance (adjusted for
baseline costs) across diagnoses and for six specific diagnoses (depression, migraine,
allergic rhinitis, asthma, atopic dermatitis, and headache).
Results
Data from 44,550 patients (67.3% females) were available for analysis. From the societal
perspective, total costs after 18 months were higher in the homeopathy group (adj. mean:
EUR 7,207.72 [95% CI 7,001.14–7,414.29]) than in the control group (EUR 5,857.56
[5,650.98–6,064.13]; p<0.0001) with the largest differences between groups for productivity
loss (homeopathy EUR 3,698.00 [3,586.48–3,809.53] vs. control EUR 3,092.84 [2,981.31–
3,204.37]) and outpatient care costs (homeopathy EUR 1,088.25 [1,073.90–1,102.59] vs.
control EUR 867.87 [853.52–882.21]). Group differences decreased over time. For all diag-
noses, costs were higher in the homeopathy group than in the control group, although this
difference was not always statistically significant.
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Conclusion
Compared with usual care, additional homeopathic treatment was associated with signifi-
cantly higher costs. These analyses did not confirm previously observed cost savings
resulting from the use of homeopathy in the health care system.
Introduction
Homeopathy is frequently used by patients in the German healthcare system. A cross-sectional
survey representative of the population indicated that 60% of all 1503 persons interviewed had
used homeopathy [1] and that 1.97% (n = 7030) of all German physicians specialize in homeop-
athy [2]. Homeopathy originates from a time when medicine would often do more harm than
good [3]. Homeopathy involves taking an elaborate patient history and prescribing homeo-
pathic remedies based on individual case histories. Homeopathy is based on the principles of
curing like with like and of diluting and shaking a substance to enhance its effectiveness [4,5].
Substances may be diluted up to a concentration in which no molecule of the original substance
can be found in the dilution [6]. Apart from Germany, homeopathy is popular among many
people around the globe, especially in Europe [7]. Its popularity stems, among other causes,
from the often extensive consultation time that homeopathic physicians provide, the absence of
adverse effects and the belief in its effects [8,9]. Despite the current lack of valid explanations for
the mechanism of action of highly diluted homeopathic remedies [6,10], homeopathy is reim-
bursed by more than 80 statutory health insurance companies in Germany [11]. In addition to
the competition for new insurants, the potential for cost savings is often used by statutory health
insurance companies as a relevant argument for reimbursing homeopathy. This cost-saving
potential has been supported by several studies that compared homeopathy with conventional
medicine [12–14]. However, our own health economic evaluations did not show a consistent
picture. We observed no differences in costs [15] or additional costs [16,17] in the homeopathic
group compared to conventional care depending on the setting or diagnosis.
A recent systematic review that summarized the available literature on cost-effectiveness
provided no distinct conclusion [7]. Homeopathy is reimbursed by German statutory health
insurance companies within the context of integrated care contracts [11], and patients can be
enrolled in integrated care contracts by their physicians. Integrated care contracts are both vol-
untarily and free of charge for the patients, participating physicians receive an additional lump
sum compensation. The aim of the integrated care contract homeopathy is to enable coopera-
tion between physicians and pharmacies to coordinate patients’ homeopathic treatments.
The objective of this study was to compare the health care costs of insured persons who
used additional homeopathic treatment within an integrated care contract framework with the
costs for patients who used only usual care through one of the largest statutory health insur-
ance companies in Germany.
Methods
Study design and participants
Health care cost data were compared for patients who used additional homeopathic treatment
within the integrated care model homeopathy (homeopathy group) and those who used only
usual care (control group) based on claims data from one of the largest German statutory
health insurance company (Techniker Krankenkasse, TK (www.tk.de)). For this analysis,
Costs of Additional Homeopathic Treatment
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patients belonged to the homeopathy group if they subscribed to the integrated care contract in
2011 and if they were continuously insured through the TK for the observational period (12
months before and 18 months after subscription to the integrated care contract), regardless of
whether they used homeopathy during the study period. The start date of the observation
period for the homeopathy group was the start date of the integrated care contract subscrip-
tion, which indicated the commencement of homeopathic treatment. The control group was
drawn from a sample of all TK-insured persons who did not subscribe to the integrated care
contract, who were continuously insured through the TK for the observational period, who
contacted a physician during the first three months of the observation period, and who were
successfully matched with a homeopathy user based on propensity scores. The start date of the
observation period for the controls was determined as the start date of the integrated care con-
tract subscription of the homeopathy users (notional start date). In addition to comparing
health care costs across diagnoses between groups, data were also analysed for specific con-
firmed diagnoses: depression (ICD-10 F32), migraine (G43), allergic rhinitis (J30), allergic
asthma (J45), atopic dermatitis (L20), and tension headache (R51). We followed the guidelines
for secondary data analyses. Patient claims data were pseudonymised by the statutory health
insurance. We had no key for de-identifying the pseudonymous data. The study was approved
by the Ethics Committee of the Charité—Universitätsmedizin Berlin (EA2/121/12).
Propensity score matching
Because any person insured through the TK could potentially subscribe to the integrated care
contract, a randomized controlled study design was not possible. To minimize selection bias
and to balance baseline characteristics between groups, homeopathy users and controls were
matched in a 1:1 ratio using propensity scores [18]. Propensity scores for the outcome ‘user of
the integrated care contract’ were calculated for participants in both groups using the following
covariates: sex (male/female), age (continuous), comorbidities (disease present, yes/no), cumu-
lative different unit costs one year prior to the study period (continuous), length of stay in a
hospital (continuous), days of sick leave (continuous) and statutory sick pay costs (continu-
ous), duration of outpatient rehabilitation (continuous), level of care intensity (‘1’, ‘2’, ‘3’ or ‘3
plus’), disease-management-program participation (yes/no), usage of GP-centred care (yes/no)
and population density (inhabitants per square kilometre, continuous). Controls were matched
to homeopathy users using the respective propensity scores with a caliper width equal to 0.25
of the standard deviation of the logit of the propensity score, which resulted in a good matching
quality. Matching was performed four times for each of the four three-month periods (quar-
ters) in 2011 to prevent seasonal effects between the groups. Matching was first performed for
each of the abovementioned diagnoses. That is, a control could be matched to a homeopathy
user with a confirmed diagnosis if the control had the same confirmed diagnosis in the same
three-month interval during which the homeopathy user subscribed to the integrated care con-
tract. Because the index date for the controls was unknown before the matching was per-
formed, cumulated costs for controls for the propensity score were calculated using the middle
of the quarter for which the matching was performed as the index date. For each of the four
matching groups, claims data were analysed for a total of 30 months, 12 months before and 18
months after the start date of the integrated care contract. Data were therefore analysed from
January 2010 to June 2013.
Economic analysis
For the primary analysis, costs were analysed from the societal perspective across all diagnoses.
For the secondary analysis, costs were analysed for the six pre-specified diagnoses. Additionally,
Costs of Additional Homeopathic Treatment
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data were analysed from the statutory health insurance perspective. Productivity loss calcula-
tions for the societal perspective were based on the human capital approach using a daily gross
mean income of EUR 239.20 with a cut-off period of six weeks [19]. Costs were not discounted
because of the short observation period. Costs were calculated 12 months prior to the start of
integrated care contract (or the notional start date for controls respectively) and 18 months after
the start of the integrated care contract. To evaluate possible sources of cost utilization in outpa-
tient care, outpatient costs were divided into costs from the homeopathic physicians who partic-
ipated in the integrated care contract and costs from other physicians. Controls could have been
treated by a homeopathic physician, but only outside of the integrated care contract. To address
interpretation issues, negative cost values in the data were set to zero.
Statistical analysis
For the primary end point, an analysis of covariance (ANCOVA) with cumulative costs of
month -12 until month 0 as the covariate was performed to compare the cumulative total costs
after 18 months between both groups. Total costs included outpatient care costs (outpatient
costs by homeopathic physicians and outpatient costs by other physicians), medication costs,
productivity loss, costs of the integrated care contract, inpatient costs and other costs. Both
total costs and single cost types were summarized for the period of 12 months before the study
onset (month -12 to month 0) and for the subsequent 18 months, divided into three-month
intervals (months 1–3, 4–6, 7–9, 10–12, 13–15, and 16–18) and compared between groups and
between diagnoses using ANCOVAs with the respective baseline cost values as a covariate.
Cost progression for the groups was compared from both the societal and statutory health
insurance perspectives over the observation period. Data on the number of days of sick leave
and number of hospital stays were compared between the groups and diagnoses. The test for
the primary end point was two-sided with a significance level of 0.05. All other tests were two-
sided with a significance level of 0.05, but were exploratory. The number of prescriptions as
well as the number of the most common diagnoses (i.e., mental and behavioural, respiratory
system, musculoskeletal system and symptoms, signs and abnormal clinical and laboratory
findings, not elsewhere classified) were analysed post-hoc and exploratory after discussing the
results of the pre-planned analyses.
Matching was performed with SAS software version 9.3 (SAS Institute Inc., Cary, U.S.). We
employed a pre-specified statistical analysis plan and used R version 3.1.0 [20] for the data
analyses.
Results
Out of all those insured in this statutory health insurance company, 4,117,726 fulfilled the
inclusion criteria. Of those 4,117,726, a sample of ten times more controls than homeopathy
patients were drawn at random for each matching process. The matching process was then
done in a 1:1 ratio. Data for 44550 patients were included in the analyses, and propensity score
matching resulted in 22275 matched pairs. The mean age was 34 years (SD 20.1) and 67.3% of
the patients were female (mean age women 35.75, SD 19.00; mean age men 30.51, SD 21.67).
The propensity score matching resulted in a comparable sample that showed no relevant differ-
ences in baseline characteristics or costs (Table 1).
The adjusted cumulative total costs 18 months after integrated care contract onset were
higher in the homeopathy group than in the control group. The adjusted mean difference of
EUR 1350.16 [95% CI 1143.59–1556.73] was statistically significant (homeopathy: adj. mean
EUR 7207.72, [7001.14–7414.29]; controls EUR 5857.56 [5650.98–6064.13], p<0.0001). The
higher costs in the homeopathy group were primarily driven by productivity loss (homeopathy
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EUR 3698.00 [3586.48–3809.53]; controls EUR 3092.84 [2981.31–3204.37]; mean difference:
605.16 [584.25–626.07], p<0.0001) and outpatient care costs (homeopathy EUR 1088.25
[1073.90–1102.59]; controls EUR 867.87 [853.52–882.21]; mean difference: 220.38 [212.88–
227.88], p<0.0001). Outpatient care costs in the homeopathic group were higher than those in
the control group for both components (i.e., both homeopathic treatments and treatments by
other physicians) (Table 2). Approximately 50% of the total costs were attributable to produc-
tivity loss. However, after productivity loss was subtracted from the total costs, the results
Table 1. Baseline characteristics of all patients. Data include the mean (SD) or the number of persons (%).
Homeopathy (n = 22275) Control (n = 22275)
Women (n) 14992 (67.3) 14968 (67.2)
Age (years) 33.85 (20.0) 34.2 (20.1)
Sick leave days previous 12 months 9.58 (35.4) 10.17 (36.4)
Hospital stays previous 12 months 0.23 (0.7) 0.21 (0.6)
Cumulated number of prescriptions previous 12 months (SD) 6.93 (10.5) 7.49 (17.7)
Cumulated costs previous 12 months
Total 1851 (5365) 1855 (5170)
Medication 304.1 (2884) 318.9 (2453)
Inpatient 556.8 (3057) 554.5 (3142)
Diagnosis (n)
Other 13479 (60.5) 13479 (60.5)
Mental and behavioural (F) 9131 (41.0) 8652 (38.8)
Depressive disorder (F33) 3072 (13.8) 3072 (13.8)
Migraine (G43) 889 (4.0) 889 (4.0)
Respiratory system (J) 12022 (54.0) 12063 (54.2)
Allergic rhinitis (J30) 1137 (5.1) 1137 (5.1)
Asthma (J45) 1247 (5.6) 1247 (5.6)
Atopic dermatitis (L20) 1488 (6.7) 1488 (6.7)
Musculoskeletal system (M) 10070 (45.2) 10080 (45.3)
Symptoms, signs and abnormal clinical and laboratory ﬁndings, not elsewhere classiﬁed (R) 10321 (46.3) 10221 (47.4)
Headache (R51) 963 (4.3) 963 (4.3)
State of residence (n)
Abroad 36 (0.2) 25 (0.1)
Baden-Wuerttemberg 3272 (14.7) 2281 (10.2)
Bavaria 2922 (13.1) 2438 (10.9)
Berlin 2256 (10.1) 1965 (8.8)
Brandenburg 432 (1.9) 546 (2.5)
Bremen 279 (1.3) 172 (0.8)
Hamburg 1274 (5.7) 1042 (4.7)
Hesse 1860 (8.4) 2027 (9.1)
Mecklenburg-Western Pomerania 236 (1.1) 386 (1.7)
Lower Saxony 2115 (9.5) 2326 (10.4)
North-Rhine Westphalia 4162 (18.7) 5812 (26.1)
Rhineland-Palatinate 878 (3.9) 974 (4.4)
Saarland 199 (0.9) 206 (0.9)
Saxony 415 (1.9) 437 (2.0)
Saxony-Anhalt 133 (0.6) 308 (1.4)
Schleswig-Holstein 1512 (6.8) 1046 (4.7)
Thuringia 294 (1.3) 284 (1.3)
doi:10.1371/journal.pone.0134657.t001
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indicated a remaining difference of EUR 719.36 [95% CI 562.53–876.19] between the groups.
Regarding productivity loss, the cost difference was explained by the difference between the
groups in terms of the number of sick leave days after 18 months. Homeopathy users were
absent from work an average of 18.77 days over 18 months [95% CI 17.96–19.58], whereas con-
trols had an average of 15.97 sick leave days [15.26–16.67] (p<0.0001) (Table 3). Sick leave
days were similar between groups for different diagnoses, except for depression, for which sick
leave days were higher in both groups. In patients with depression, the mean number of sick
leave days in the homeopathy group was 48.21 [95% CI 44.57–51.84] compared to 41.97
[38.63–45.31] in the control group (p = 0.013). The mean number of hospital stays was 0.48 in
the control group [95% CI 0.45–0.52] compared with 0.61 [0.57–0.66] in homeopathy users
with depression (p<0.0001).
Regarding disease-specific costs, patients with depression accounted for most of these costs.
Among the group suffering from depression, the adjusted cumulative total costs were higher in
the homeopathy group than in the control group (homeopathy adj. mean: EUR 15084.49, [95%
CI 14460.27–15708.71]; controls EUR 12797.66 [12173.44–13421.88], p<0.0001) (Table 4).
For the breakdown of total costs in specific diagnosis subgroups, see S1 Table.
Table 2. Adjustedmeans for different cost types over 18 months after the start of the integrated care contract for all patients, societal perspective.
Homeopathy (n = 22275) Control (n = 22275)
Type of cost N Cost utilization Adj. mean (EUR) (95% CI) N Cost utilization Adj. mean (EUR) (95% CI) p-value
Integrated care contract 22272 228.00 (226.66–229.35) – – <0.0001
Outpatient 22271 1088.25 (1073.90–1102.59) 22275 867.87 (853.52–882.21) <0.0001
Homeopathic physician 21658 165.32 (163.45–167.20) 606 25.50 (23.62–27.37) <0.0001
Other physicians 21802 950.49 (933.17–967.80) 22275 856.37 (839.06–873.69) <0.0001
Medication 19638 773.27 (656.37–890.17) 20166 579.64 (462.74–696.54) 0.022
Productivity loss 7960 3698.00 (3586.48–3809.53) 7954 3092.84 (2981.31–3204.37) <0.0001
Inpatient 4702 959.65 (904.08–1015.22) 4334 821.90 (766.33–877.47) 0.001
Other 20604 56.21 (54.54–57.88) 17538 54.64 (52.96–56.31) 0.192
Total 22275 7207.72 (7001.14–7414.29) 22275 5857.56 (5650.98–6064.13) <0.0001
doi:10.1371/journal.pone.0134657.t002
Table 3. Mean cumulative sick leave days, number of hospital stays, diagnoses and prescriptions over 18 months after the start of the integrated
care contract for different diagnoses.
Homeopathy Control
Variable N
utilization
Mean (95% CI) N
utilization
Mean (95% CI) p-value
Sick leave days 7960 18.77 (17.96–
19.58)
7954 15.97 (15.26–
16.67)
<0.0001
Number of hospital stays 4709 0.36 (0.34–0.37) 4344 0.31 (0.30–0.32) <0.0001
Cumulative number of diagnoses
Mental and behavioural (F) 13450 0.60 (0.60–0.61) 9774 0.44 (0.43–0.45) 0.03
Respiratory system (J) 15385 0.69 (0.68–0.70) 14096 0.63 (0.63–0.64) <0.0001
Musculoskeletal system (M) 13175 0.59 (0.59–0.60) 11956 0.54 (0.53–0.54) 0.033
Symptoms, signs and abnormal clinical and laboratory ﬁndings, not
elsewhere classiﬁed (R)
14978 0.67 (0.67–0.68) 12254 0.55 (0.54–0.56) <0.0001
Number of prescriptions 19851 10.40 (10.2–
10.6)
20233 10.69 (10.5–
10.9)
0.034
doi:10.1371/journal.pone.0134657.t003
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From both the societal and statutory health insurance perspectives, the cost progression was
similar in both groups from month -12 to month 0 (cumulative costs from month -12 to
month 0 from the societal perspective: homeopathy mean EUR 3669 [95% CI 3553–3785]; con-
trols mean EUR 3776 [3662–3890]; statutory health insurance: homeopathy mean EUR 1851
[1780–1921]; controls mean EUR 1855 [1788–1923]). The greatest cost difference could be
observed in months 1–3 (societal perspective: homeopathy mean EUR 1382 [1336–1429]; con-
trols mean EUR 1051 [1011–1090]; statutory health insurance perspective: homeopathy mean
EUR 718.5 [687.6–749.3]; controls mean EUR 498.3 [474.3–522.4]). This substantial difference
largely resulted from the costs for initial homeopathic consultations. Costs progressed similarly
from both the societal and statutory health insurance perspectives. From both perspectives, the
costs for the homeopathy group were higher than those for the control group for the entire
observation period. However, by the end of the observation period (month 18), the gap
between the two groups had decreased (Fig 1). The number of prescriptions for homeopathic
patients was lower than that for control patients after 18 months (homeopathy mean 10.4
[95% CI 10.2–10.6]; controls mean 10.7 [10.5–10.9], p = 0.038). The costs for medication after
18 months differed between the groups (homeopathy adj. mean EUR 773.27 [95% CI 656.37–
890.17]; controls EUR 579.64 [462.74–696.54], p = 0.022). After 18 months, the mean number
of diagnoses was higher in the homeopathic group than in the control group for all observed
diagnoses (Table 3).
Discussion
Key results
Our analysis showed that adjusted total health care costs after 18 months across diagnoses
were higher in the homeopathy group compared to the control group. The cost difference was
primarily attributable to productivity loss and outpatient care costs. Group differences
decreased over time.
Strengths and limitations
This study used claims data from a large statutory health insurance company for secondary
data analyses, resulting in a sample size of 44550 patients, including 22275 subscribers to the
integrated care contract homeopathy. We used cumulative different unit costs for 12 months
prior to the integrated care contract as a covariate for the propensity score. The nature of sec-
ondary data used in our study does not allow to draw conclusions about the severity of the
patients’ diseases. However, health care costs can serve as a proxy for a medical condition or
Table 4. Adjustedmeans for total costs for different diagnoses over 18 months after the start of the integrated care contract for all patients, socie-
tal perspective.
Homeopathy Control
Diagnosis N Cost utilization Adj. mean (EUR) (95% CI) N Cost utilization Adj. mean (EUR) (95% CI) p-value
All 22275 7207.72 (7001.14–7414.29) 22275 5857.56 (5650.98–6064.13) <0.0001
Depression 3072 15084.49 (14460.27–15708.71) 3072 12797.66 (12173.44–13421.88) <0.0001
Migraine 889 8512.25 (7644.90–9379.59) 889 7115.62 (6248.27–7982.97) 0.026
Allergic rhinitis 1137 5763.05 (5252.59–6273.51) 1137 4642.93 (4132.47–5153.39) 0.002
Asthma 1247 6937.04 (6351.49–7522.60) 1247 5541.33 (4955.77–6126.88) 0.001
Atopic dermatitis 1488 4256.71 (3922.12–4591.31) 1488 3426.10 (3091.50–3760.70) 0.001
Headache 963 7597.46 (6783.55–8411.37) 963 6279.82 (5465.90–7093.73) 0.025
doi:10.1371/journal.pone.0134657.t004
Costs of Additional Homeopathic Treatment
PLOS ONE | DOI:10.1371/journal.pone.0134657 July 31, 2015 7 / 11
for the severity of a disease [21]. Therefore we reduced the variances of unknown variables
responsible for the cost differences between the two groups. The matching resulted in compa-
rable groups with respect to the considered covariates, confirmed by both the analysis at base-
line and the pre-baseline cost progression analyses. We analysed a number of types of costs,
including productivity loss, and were therefore able to consider costs from both the payer and
societal perspectives.
A limitation of our study is that it was restricted to costs; therefore, we were unable to evalu-
ate the effectiveness of the integrated care contract. Approximately 40% of the patients were
matched according to a confirmed diagnosis. However, the patients’ reasons, primary or other-
wise, for visiting a physician during the first three months of the observation period were
unknown. For example, two patients could have been matched for the diagnosis of asthma
although one of the matches might have also experienced and sought treatment for a costly car
accident. However, such a situation could have occurred in both groups; because the matching
also involved costs, we assume that we balanced the burden of disease in both groups. Another
limitation of our study is the relatively short observation period of 18 months. Given that the
Fig 1. Mean overall cost (EUR) progression by group from the societal and statutory health insurance perspectives frommonth -12 until month 18.
Error bars denote 95% CIs. Months 1 to 3 indicate the start of the integrated care model. Costs frommonth 1 on adjusted to baseline costs (month -12 to
month 0)
doi:10.1371/journal.pone.0134657.g001
Costs of Additional Homeopathic Treatment
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costs for both groups appeared to converge at the end of the observation period, a longer obser-
vation period would have been desirable. Homeopathic treatment could be associated with ini-
tial higher investments that decline over longer courses of treatment. However, the data
available for our study did not allow for testing this assumption. Regarding the generalizability
of our results, approximately two-thirds of our sample comprised female participants, reflect-
ing the current literature on predictions for complementary medicine usage [22]. Furthermore,
the generalizability of our results is limited because we used data from only one statutory health
insurance company. Historically, the clients of this health insurance company are younger and
better educated than clients from other health insurance companies. Moreover, patients who
subscribe to the integrated care contract may differ from patients who do not subscribe in
terms of unobservable factors, such as lifestyle factors or health consciousness. Unfortunately,
these factors were unknown to us, and we could not adjust for them. Another limitation is that
neither homeopathic remedies nor over-the-counter drugs paid for out of pocket could be con-
sidered in the analyses from the societal perspective. This limitation might have resulted in an
underestimation of costs for both groups.
Interpretation
A recent systematic review by Viksveen on the cost-effectiveness of homeopathy showed that
in eight out of fourteen studies, the homeopathic treatment was less cost-intensive than the
conventional treatment; in four studies, the treatment costs were similar; and in two studies,
the homeopathic treatment was more costly than conventional treatment [7]. However, the
review also indicated that the included economic evaluations of homeopathy were heteroge-
neous and lacked methodological quality. A recent Dutch secondary data analysis compared
health care costs for patients treated by a conventional GP compared with patients treated by a
GP trained in complementary and alternative medicine (CAM) for six years. The researchers
reported that the annual health care costs for patients treated by a CAM-GP were nearly EUR
200 lower than the costs for patients treated by a conventional GP [14]. Unfortunately, the
authors did not present subgroup analyses for different types of CAM. In their analyses, the
researchers did not adjust for baseline costs and did not explore comorbidities or longitudinal
cost progressions. Overall, the literature on the costs of homeopathic treatment has not reached
a clear conclusion. Furthermore, because of differences in health care systems, the transferabil-
ity of health economics results from one country to another is limited [23]. Therefore, our
study adds important knowledge to this body of literature.
The Viksveen review reported that the most relevant cost driver in homeopathic treatment
are consultation costs and that overall medication costs are often reduced for homeopathic
treatment compared with conventional practices [7]. By contrast, our results showed that a
cost increase for homeopathic patients could be observed for many types of costs, including
costs for medications, outpatient care, and productivity loss. For the increase in conventional
medication costs that we observed, two explanations might be applicable: either homeopathic
physicians who were also conventionally trained prescribed them, or patients sought more con-
ventional care from other physicians. Detailed post hoc analyses of prescriptions showed that
although homeopathic patients had higher medication costs, the number of prescriptions was
similar in both groups. Homeopathic patients might therefore have been prescribed higher-
priced medications. Interestingly, homeopathic patients received three-quarters of their con-
ventional drug prescriptions from other physicians. Many patients seeking treatment from
homeopaths are chronically ill [24]. Patients under integrated care contracts might be better
integrated into the health system than other chronically ill patients. In general, homeopathic
treatment follows a more holistic approach that considers the whole person and his or her
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resources. This approach could result in diagnosing and treating other somatic or mental disor-
ders as well and in more frequently providing patients with sick leave notes allowing them to
rest. This more holistic approach could lead to the initiation of further conventional care,
which is associated with additional costs. This possible situation might explain why the homeo-
pathic group had more diagnoses after 18 months, with a peak at the beginning of the inte-
grated care contract, although the numbers of diagnoses were comparable between the groups
at baseline. In months 1–3, considering all diagnosis groups, homeopathic patients had 126.2%
more diagnoses than the controls did. The greatest difference between the groups was observed
for mental health diagnoses (38.9%). The difference in the observed number of diagnoses after
the beginning of the integrated care contract might be explained by some patients who visited
the homeopathic physician for the first time and the associated extensive initial consultation
including broader diagnostics. This could have been a reason for higher cost. However, we do
not have any data available to support that claim. Another explanation for the difference in the
number of diagnoses might be that homeopathic physicians who participated in the integrated
care contract might have provided more thorough documentation even for their own patients
because of the new contact format, thus resulting in more diagnoses.
Conclusion
The analyses of our present study did not confirm the previously observed cost savings result-
ing from the use of homeopathy in the health care system. In an 18-month integrated care pro-
gram that offered and reimbursed homeopathy in addition to usual care, patients who used
additional homeopathic treatment had significantly higher costs compared with patients who
received only usual care.
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